(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -22.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.46%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.4%.
Cytomx Therapeutics's revenue in 2026 is $113,631,000.On average, 10 Wall Street analysts forecast CTMX's revenue for 2026 to be $7,133,399,565, with the lowest CTMX revenue forecast at $664,186,748, and the highest CTMX revenue forecast at $18,146,530,805. On average, 8 Wall Street analysts forecast CTMX's revenue for 2027 to be $9,151,036,249, with the lowest CTMX revenue forecast at $0, and the highest CTMX revenue forecast at $19,925,602,452.
In 2028, CTMX is forecast to generate $8,452,454,115 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $15,068,736,854.